Cole Schmidtknecht, 22, couldn't pay for his daily inhaler due to the “prohibitively expensive” price increase, but then he ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth?

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...

The FTSE 100 rose by 0.6%, propelled by surges in GSK and gold mining shares, as market focus shifted toward the Bank of ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...